Get the latest tech news
Where Are All the AI Drugs?
In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.
Founded 12 years ago by academics in Utah, the company made its name by taking snapshots of cells under various conditions, creating a vast database of pictures, and turning AI on them to identify potential new targets. In a global competition that fall, an AI built by Alphabet’s DeepMind showed it could correctly predict how a protein would fold up into its final form—a canonical hard problem in biology and a key task for drug hunters. This critical mass, with information going public in a large bolus, is a calculated goal, he said: If around 90 percent of drugs fail, then Recursion needs to show results of about 10 different programs just to see if they are doing what they hope.
Or read this on Wired